Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Premium Services
Financial News
Latest
Earnings
Guidance
Dividends
M&A
Buybacks
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Small-Cap
Markets
Pre-Market
After Hours
Movers
ETFs
Options
Cryptocurrency
Commodities
Bonds
Futures
Mining
Real Estate
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Investing Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
Analyst Ratings
Analyst Color
Latest Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Unusual Options Activity Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Compare Best Stocks

Best Momentum Stocks

Best Quality Stocks

Best Value Stocks

Best Growth Stocks

Comments

Loading...

Otsuka Holdings Stock News

OTSKYOTCPK

Logo brought to you by Benzinga Data

Trade with Public

Trade with Public

$29.90

0.240.81%

At close: Dec 15, 4:00 PM EST

$27.13

-2.77-9.26%

After Hours: Nov 21, 8:01 AM EST

News

Earnings Guidance Dividends Short Interest Government Trades

Latest Otsuka Holdings Stock News | OTC:OTSKY | Benzinga

Get the latest news on Otsuka Holdings stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Otsuka Holdings performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, October 16, 2025

Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market
Vandana Singh

Tuesday, December 31, 2024

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
Vandana Singh

Thursday, October 31, 2024

Otsuka Holdings Q3 EPS $0.52 Up From $0.38 Yo...
Benzinga Newsdesk

Tuesday, April 16, 2024

IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
Vandana Singh

Wednesday, March 20, 2024

Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
Vandana Singh

Monday, September 18, 2023

One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
Faith Ashmore - Sponsored

Thursday, August 24, 2023

Regulatory Setback For Medtronic's High Blood Pressure Device - FDA Backed Japanese Firms' Similar Device For Uncontrolled Hypertension
Vandana Singh

Wednesday, August 23, 2023

Individuals With Uncontrolled Hypertension - FDA Adcomm Panel Just Supported Japanese MedTech's Blood Pressure Treatment Device
Vandana Singh

Thursday, May 11, 2023

FDA Approves First Drug To Treat Agitation Symptoms Associated With Dementia Due To Alzheimer's Disease
Happy Mohamed
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
Vandana Singh

Thursday, November 03, 2022

Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches
Nick Thomas - Sponsored

Wednesday, August 17, 2022

This Upstart Supplement Company Says It's Making Huge Strides In Selling Its Well-Told Story
Mark Gilman - Sponsored

Friday, August 05, 2022

Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
Vandana Singh

Friday, July 01, 2022

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Vandana Singh

Monday, May 16, 2022

Why Are Akebia Therapeutics Shares Falling Today?
Vandana Singh

Wednesday, March 30, 2022

FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia
Vandana Singh

Tuesday, June 01, 2021

Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
Vandana Singh

Friday, January 15, 2021

Novavax Hires Regulatory Expert As Coronavirus Vaccine Inches Closer To Emergency Use Filing
Shanthi Rexaline

Wednesday, November 25, 2020

JD.com Unit Set For Asia's Largest-Ever Healthcare IPO Above $3B
Aditya Raghunath

Friday, August 07, 2020

Earnings Scheduled For August 7, 2020
Benzinga Insights

Tuesday, March 24, 2020

Stocks That Hit 52-Week Highs On Tuesday
Benzinga Insights

Friday, January 10, 2020

Stocks That Hit 52-Week Highs On Friday
Lisa Levin

Monday, December 23, 2019

Stocks That Hit 52-Week Highs On Monday
Lisa Levin

Friday, December 20, 2019

Stocks That Hit 52-Week Highs On Friday
Lisa Levin

Thursday, August 24, 2017

Otsuka, Mylan Announce License Agreement to Commercialize Delamanid for MDR-TB in High-Burden Countries
Benzinga

Thursday, April 27, 2017

4 Things To Know About Akebia's New Vadadustat Collaboration With Otsuka Pharma
Benzinga

Sunday, December 07, 2014

FDA Approves Labeling Update of Abilify Maintena for Extended-Release Injectable Suspension
Benzinga

Tuesday, December 02, 2014

Benzinga's M&A Chatter for Tuesday December 2, 2014
Benzinga
UPDATE: Otsuka to Acquire Avanir for $17.00/S...
Benzinga
Avanir Pharmaceuticals to be Acquired by Otsuka Pharmaceutical for $3.5B
Benzinga

Monday, October 07, 2013

Astex Pharmaceuticals Announces Expiration of HSR Waiting Period for Otsuka Tender Offer
Benzinga

Friday, April 12, 2013

Otsuka's NDA for Tolvaptan for Autosomal Dominant Polycystic Kidney Disease , Accepted for Review by FDA
Benzinga

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved